Page last updated: 2024-08-24

valsartan and Prediabetes

valsartan has been researched along with Prediabetes in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Califf, RM; Gray, AM; Holman, RR; Leal, J; Li, Y; Patel, R; Reed, SD; Rivero-Arias, O; Schulman, KA	1
Goldstein, BA; Holman, RR; Pagidipati, NJ; Pencina, MJ; Phelan, M; Stuart, EA	1
Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR	1
Bakris, GL; Cuadra, RH; Kupfer, S; Lloyd, E; White, WB	1
Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH	1
Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L	1
Ofili, EO; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH	1

Trials

6 trial(s) available for valsartan and Prediabetes

Article	Year
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes care, 2020, Volume: 43, Issue:10 Topics: Adult; Age of Onset; Aged; Benchmarking; Cardiometabolic Risk Factors; Cardiovascular Diseases; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Mortality; Prediabetic State; Primary Prevention; Quality of Life; Quality-Adjusted Life Years; United Kingdom; United States; Valsartan	2020
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation. Heart failure, 2016, Volume: 9, Issue:1 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left	2016
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. Journal of hypertension, 2016, Volume: 34, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Middle Aged; Oxadiazoles; Prediabetic State; Tetrazoles; Valsartan	2016
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:12 Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Risk Factors; Tetrazoles; Valine; Valsartan; Young Adult	2008
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovascular therapeutics, 2010, Volume: 28, Issue:2 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan	2010
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. American journal of therapeutics, 2013, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Insulin; Intention to Treat Analysis; Male; Middle Aged; Obesity, Abdominal; Prediabetic State; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People	2013

Other Studies

1 other study(ies) available for valsartan and Prediabetes

Article	Year
An outcome model approach to transporting a randomized controlled trial results to a target population. Journal of the American Medical Informatics Association : JAMIA, 2019, 05-01, Volume: 26, Issue:5 Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan	2019

Article

Year

An outcome model approach to transporting a randomized controlled trial results to a target population.

Journal of the American Medical Informatics Association : JAMIA, 2019, 05-01, Volume: 26, Issue:5

Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan

2019